View Future GrowthNexgenRx 過去の業績過去 基準チェック /56NexgenRxの収益は年間平均-35.5%の割合で減少していますが、 Insurance業界の収益は年間 増加しています。収益は年間14.6% 11.1%割合で 増加しています。 NexgenRxの自己資本利益率は22.6%であり、純利益率は9.5%です。主要情報-35.47%収益成長率-35.67%EPS成長率Insurance 業界の成長8.02%収益成長率11.09%株主資本利益率22.58%ネット・マージン9.54%前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.お知らせ • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.お知らせ • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.お知らせ • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.お知らせ • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.お知らせ • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.お知らせ • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.お知らせ • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.収支内訳NexgenRx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:NEGX.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Mar 2618211031 Dec 2518111030 Sep 2518111030 Jun 2517111031 Mar 2517011031 Dec 2416011030 Sep 2416011030 Jun 2415011031 Mar 2415010031 Dec 2314-110030 Sep 231409030 Jun 231309031 Mar 231309031 Dec 221308030 Sep 221338030 Jun 221347031 Mar 221247031 Dec 211246030 Sep 211126030 Jun 211126031 Mar 211126031 Dec 201127030 Sep 201017030 Jun 201007031 Mar 201008031 Dec 191007030 Sep 19907030 Jun 19907031 Mar 19807031 Dec 187-16030 Sep 186-16030 Jun 186-15031 Mar 186-15031 Dec 176-15030 Sep 17604030 Jun 17604031 Mar 17614031 Dec 16614030 Sep 16504030 Jun 16504031 Mar 16504031 Dec 15504030 Sep 15504030 Jun 154040質の高い収益: NEGX.Fは 高品質の収益 を持っています。利益率の向上: NEGX.Fの現在の純利益率 (9.5%)は、昨年(2.9%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NEGX.Fの収益は過去 5 年間で年間35.5%減少しました。成長の加速: NEGX.Fの過去 1 年間の収益成長率 ( 264.5% ) は、5 年間の平均 ( 年間-35.5%を上回っています。収益対業界: NEGX.Fの過去 1 年間の収益成長率 ( 264.5% ) はInsurance業界36.2%を上回りました。株主資本利益率高いROE: NEGX.Fの 自己資本利益率 ( 22.6% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YInsurance 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 06:51終値2026/03/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NexgenRx Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.
お知らせ • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.
お知らせ • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.
お知らせ • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.
お知らせ • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.
お知らせ • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.
お知らせ • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.
お知らせ • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.
お知らせ • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.
お知らせ • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.
お知らせ • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.
お知らせ • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.
お知らせ • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.
お知らせ • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.
お知らせ • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.